Cargando…

SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19

BACKGROUND: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hannah, Hogan, Catherine A, Verghese, Michelle, Solis, Daniel, Sibai, Mamdouh, Huang, ChunHong, Röltgen, Katharina, Stevens, Bryan A, Yamamoto, Fumiko, Sahoo, Malaya K, Zehnder, James, Boyd, Scott D, Pinsky, Benjamin A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522398/
https://www.ncbi.nlm.nih.gov/pubmed/34605900
http://dx.doi.org/10.1093/clinchem/hvab216
_version_ 1784585080683888640
author Wang, Hannah
Hogan, Catherine A
Verghese, Michelle
Solis, Daniel
Sibai, Mamdouh
Huang, ChunHong
Röltgen, Katharina
Stevens, Bryan A
Yamamoto, Fumiko
Sahoo, Malaya K
Zehnder, James
Boyd, Scott D
Pinsky, Benjamin A
author_facet Wang, Hannah
Hogan, Catherine A
Verghese, Michelle
Solis, Daniel
Sibai, Mamdouh
Huang, ChunHong
Röltgen, Katharina
Stevens, Bryan A
Yamamoto, Fumiko
Sahoo, Malaya K
Zehnder, James
Boyd, Scott D
Pinsky, Benjamin A
author_sort Wang, Hannah
collection PubMed
description BACKGROUND: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity. METHODS: We utilized an ultrasensitive electrochemiluminescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected ±1 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2–negative individuals. We used Kruskal–Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity. RESULTS: Plasma antigen had 91.9% (95% CI 83.2%–97.0%) clinical sensitivity and 94.2% (84.1%–98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (C(t)) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log(10) fg/mL) was 5.4 (interquartile range 3.9–6.0) in outpatients, 6.0 (5.4–6.5) in inpatients, and 6.6 (6.1–7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2–6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity. CONCLUSIONS: SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory C(t). In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization.
format Online
Article
Text
id pubmed-8522398
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-85223982021-10-20 SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19 Wang, Hannah Hogan, Catherine A Verghese, Michelle Solis, Daniel Sibai, Mamdouh Huang, ChunHong Röltgen, Katharina Stevens, Bryan A Yamamoto, Fumiko Sahoo, Malaya K Zehnder, James Boyd, Scott D Pinsky, Benjamin A Clin Chem Articles BACKGROUND: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity. METHODS: We utilized an ultrasensitive electrochemiluminescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected ±1 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2–negative individuals. We used Kruskal–Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity. RESULTS: Plasma antigen had 91.9% (95% CI 83.2%–97.0%) clinical sensitivity and 94.2% (84.1%–98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (C(t)) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log(10) fg/mL) was 5.4 (interquartile range 3.9–6.0) in outpatients, 6.0 (5.4–6.5) in inpatients, and 6.6 (6.1–7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2–6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity. CONCLUSIONS: SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory C(t). In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization. Oxford University Press 2021-10-04 /pmc/articles/PMC8522398/ /pubmed/34605900 http://dx.doi.org/10.1093/clinchem/hvab216 Text en © American Association for Clinical Chemistry 2021. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Wang, Hannah
Hogan, Catherine A
Verghese, Michelle
Solis, Daniel
Sibai, Mamdouh
Huang, ChunHong
Röltgen, Katharina
Stevens, Bryan A
Yamamoto, Fumiko
Sahoo, Malaya K
Zehnder, James
Boyd, Scott D
Pinsky, Benjamin A
SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19
title SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19
title_full SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19
title_fullStr SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19
title_full_unstemmed SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19
title_short SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19
title_sort sars-cov-2 nucleocapsid plasma antigen for diagnosis and monitoring of covid-19
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522398/
https://www.ncbi.nlm.nih.gov/pubmed/34605900
http://dx.doi.org/10.1093/clinchem/hvab216
work_keys_str_mv AT wanghannah sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT hogancatherinea sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT verghesemichelle sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT solisdaniel sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT sibaimamdouh sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT huangchunhong sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT roltgenkatharina sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT stevensbryana sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT yamamotofumiko sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT sahoomalayak sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT zehnderjames sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT boydscottd sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19
AT pinskybenjamina sarscov2nucleocapsidplasmaantigenfordiagnosisandmonitoringofcovid19